Results from a 9-year Intensive Safety Surveillance Scheme (IS 3 ) in miglustat (Zavesca ® )-treated patients
Brand, Monika, Muller, Audrey, Alsop, Jonathan, van Schaik, Ivo N., Bembi, Bruno, Hughes, DerralynnVolume:
24
Language:
english
Journal:
Pharmacoepidemiology and Drug Safety
DOI:
10.1002/pds.3760
Date:
March, 2015
File:
PDF, 196 KB
english, 2015